Full-Time

Associate Director

Scientific Communications

Posted on 9/9/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$165k - $214.5k/yr

+ Annual bonus + Long-term incentive award

Boston, MA, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday.

Master's, PharmD, PhD

Category
Biology & Biotech

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A PhD, PharmD, MS, or equivalent advanced scientific degree.
  • At least 7 years of experience in scientific communications, medical affairs, or related roles within the biotechnology or pharmaceutical industry.
  • Experience supporting publication strategy and congress execution, ideally for late-stage Phase 2/3 or Phase 3 programs.
  • Deep knowledge of scientific publication standards, data disclosure requirements, and medical compliance, including GPP2022 and ICMJE guidelines.
  • Strong project management and organizational skills, with the ability to manage multiple concurrent timelines.
  • Ability to build credibility with cross-functional partners across Clinical Development, Regulatory, Commercial, and Medical Affairs.
  • Ability to exercise sound judgment and independent problem-solving in a fast-paced, resource-constrained environment.
  • Ability to translate complex clinical and scientific data into clear, audience-appropriate narratives for diverse stakeholders.
  • Ability to communicate proactively with cross-functional partners on publication timelines, congress deliverables, and project status.
  • Ability to ensure consistency, accuracy, and compliance of scientific messaging across all channels and materials.
  • Ability to collaborate effectively with clinical, regulatory, and commercial colleagues to align on scientific narrative.
Responsibilities
  • Support development and lead execution of the scientific communications plan in alignment with asset strategy and medical affairs objectives.
  • Manage global publication activities, including author engagement, abstracts, manuscripts, posters, and oral presentations, in compliance with GPP2022 and company standard operating procedures.
  • Oversee execution of plans for major international and regional medical meetings, including content development and internal alignment.
  • Draft and edit scientific content, including slide decks, scientific exchange materials, frequently asked questions, and training resources for Field Medical teams.
  • Partner with cross-functional teams to ensure accurate interpretation and timely dissemination of data.
  • Maintain publication trackers and timelines, and manage vendor and agency relationships to ensure on-time, on-budget delivery.
  • Support advisory boards, investigator meetings, and external scientific forums.
  • Assist in establishing processes and standards to ensure consistency and compliance across scientific materials.
  • Perform other duties and responsibilities as assigned.
  • Contribute to a culture of scientific excellence, accountability, and continuous improvement within the scientific communications function.
Desired Qualifications
  • Experience in autoimmune, immunology, or inflammatory diseases.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...